eurestobart (ES002) / Elpiscience - LARVOL DELTA

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: Elpiscience Biopharma, Ltd. | Active, not recruiting ➔ Completed | N=60 ➔ 8

Enrollment change • Trial completion • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: Elpiscience Biopharma, Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Elpiscience Announces CDE Clearance of IND Application for Anti-CD39 Monoclonal Antibody ES002 (Businesswire) - "Elpiscience Biopharmaceuticals...announced that the Center of Drug Evaluation (CDE) has cleared Elpiscience’s Investigational New Drug Application (IND) for ES002 to initiate a Phase I clinical trial in China. ES002 is a proprietary anti-CD39 monoclonal antibody (mAb), which has demonstrated highly potent single-agent anti-tumor activity showing a significant reduction in tumor size in in vivo pharmacology studies....'We look forward to initiating the study in China and potential clinical benefits ES002 may offer for patients with solid tumors worldwide'."

New P1 trial • Oncology • Solid Tumor

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Elpiscience Biopharma, Ltd.; Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors (Businesswire) - "Elpiscience Biopharmaceuticals...announced that the first patient has been dosed in a U.S. multi-center, Phase I clinical trial, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES002, the company’s proprietary anti-CD39 monoclonal antibody (mAb), that is being developed for the treatment of advanced solid tumors (NCT05075564)."

Trial status • Oncology • Solid Tumor

ES002: IND submission in US in July 2021 (Jefferies 2021 Virtual Healthcare Conference (Virtual Meeting), Elpiscience)

IND • Oncology

ES002: IND submission in US in July 2021 (Jefferies 2021 Virtual Healthcare Conference (Virtual Meeting), Elpiscience)

IND • Oncology